{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"12.2","spread":"12.2","upperLimit":"73.8","value":"40.0"},{"groupId":"OG001","lowerLimit":"19.1","spread":"19.1","upperLimit":"63.9","value":"40.0"},{"groupId":"OG002","lowerLimit":"6.7","spread":"6.7","upperLimit":"65.2","value":"30.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"20"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"DCR was defined as percentage of participants with confirmed CR, PR, or SD (SD duration greater than or equal to \\[\\>=\\] 7 weeks since first dose of study treatment) divided by number of participants in analysis set. DCR was assessed by investigator based on RECIST v1.1 for non-HGG cohorts or RANO for HGG cohort. CR: disappearance of all target and non-target lesions (non-lymph nodes). All pathological lymph nodes (whether target or non-target) must have a reduction in their short axis \\<10 mm. PR: at least a 30% decrease in the SOD of target lesions, taking as reference the baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest SOD. PD: at least 20% increase (including an absolute increase of at least 5 mm) in the SOD of target lesions, taking as reference the smallest sum and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent or refractory ewing sarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG000","title":"Phase 2: Cohort 1, Ewing Sarcoma"},{"description":"Participants with recurrent or refractory rhabdomyosarcoma received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG001","title":"Phase 2: Cohort 2, Rhabdomyosarcoma"},{"description":"Participants with recurrent or refractory HGG received lenvatinib 11 mg/m\\^2, capsules, orally, once daily in combination with everolimus 3 mg/m\\^2, tablets, orally, once daily for up to 7 cycles (each cycle was 28 days) unless participant discontinued early from the study.","id":"OG002","title":"Phase 2: Cohort 3, HGG"}],"paramType":"NUMBER","populationDescription":"Evaluable analysis set included all evaluable participants who have measurable disease present at baseline, and at least one postbaseline efficacy assessment, unless they have discontinued prior to the first efficacy assessment due to progressive disease.","reportingStatus":"POSTED","timeFrame":"From first dose of study drug until PD or death, whichever occurred first (up to 6.5 months)","title":"Phase 2: Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}